Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S55
- Development stage
- Preclinical
- Lead developer
- Justus Liebig University Giessen
- Modality
- Small Molecules
01
Overview
S55 is a novel small molecule transient receptor potential (TRP) channel activator developed to treat neglected tropical diseases caused by parasitic flatworms. It acts as a dual agonist of the transient receptor potential melastatin praziquantel channel (TRPMPZQ) orthologs in both *Schistosoma mansoni* (Sm.TRPMPZQ) and *Fasciola hepatica* (Fh.TRPMPZQ) with submicromolar potency. Unlike praziquantel, which is ineffective against *Fasciola* species due to structural variations in their TRPMPZQ binding pocket, S55 is designed to tolerate these variations. Ex vivo, S55 induces rapid contraction and tegumental damage in both *S. mansoni* and triclabendazole-sensitive or triclabendazole-resistant *F. hepatica*. S55 has demonstrated a favorable safety profile in HepG2 assays and is active and well-tolerated in vivo.
Beyond the preview
Go deeper on S55.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S55.